Compare Cytokinetics Inc (CYTK) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Sprott Uranium Miners ETF — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Sprott Uranium Miners ETF trades at $46.5 (market cap $1.87B). The key difference: Cytokinetics Inc is far larger — about 4.6× Sprott Uranium Miners ETF's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Sprott Uranium Miners ETF for 61 Days on average.
| CYTK | URNM | |
|---|---|---|
Market Cap | $8.62B | $1.87B |
Volume | 2,594,626 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $87.26 | $83.99 |
52-Week Low | $54.76 | $46.09 |
Typical Hold Time | 19 Days | 61 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
URNM (Sprott Uranium Miners ETF) trades at $46.09, down 3.72% today amid bearish technical signals. The ETF shows strong fundamental support from uranium's supply-demand imbalance and growing AI energy demand. Recent news highlights nuclear energy's resurgence, with uranium prices rising 21.25% over the past year according to Sprott Asset Management data from August 2026.
Long-term outlook remains positive due to structural uranium deficits and government nuclear investments, but short-term technical weakness and ETF volatility present near-term risks. The convergence of AI power demand and nuclear expansion creates substantial growth potential for uranium miners over the next decade.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
